Profound Medical Corp has a consensus price target of $14.63 based on the ratings of 7 analysts. The high is $23 issued by Raymond James on February 22, 2022. The low is $10 issued by Jefferies on March 21, 2023. The 3 most-recent analyst ratings were released by Stifel, Alliance Global Partners, and Stifel on July 16, 2024, March 11, 2024, and March 8, 2024, respectively. With an average price target of $10.6 between Stifel, Alliance Global Partners, and Stifel, there's an implied 6.00% upside for Profound Medical Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/16/2024 | Buy Now | 20% | Stifel | Rick Wise | $9 → $12 | Upgrade | Hold → Buy | Get Alert |
03/11/2024 | Buy Now | 8% | Alliance Global Partners | Ben Haynor | $12.75 → $10.8 | Maintains | Buy | Get Alert |
03/08/2024 | Buy Now | -10% | Stifel | Rick Wise | $11 → $9 | Maintains | Hold | Get Alert |
01/04/2024 | Buy Now | 27.5% | Alliance Global Partners | Ben Haynor | $14.25 → $12.75 | Maintains | Buy | Get Alert |
11/28/2023 | Buy Now | 10% | Stifel | Rick Wise | → $11 | Initiates | → Hold | Get Alert |
08/04/2023 | Buy Now | — | Raymond James | Rahul Sarugaser | — | Downgrade | Strong Buy → Outperform | Get Alert |
05/11/2023 | Buy Now | 80% | TD Cowen | Joshua Jennings | $14 → $18 | Maintains | Outperform | Get Alert |
05/11/2023 | Buy Now | 57.5% | Alliance Global Partners | Ben Haynor | $13.15 → $15.75 | Maintains | Buy | Get Alert |
03/21/2023 | Buy Now | — | Jefferies | Michael Sarcone | $5.5 → $10 | Downgrade | Buy → Equal-Weight | Get Alert |
11/04/2022 | Buy Now | — | Raymond James | Rahul Sarugaser | — | Upgrade | Outperform → Strong Buy | Get Alert |
03/07/2022 | Buy Now | 40% | Cowen & Co. | Joshua Jennings | $28 → $14 | Maintains | Outperform | Get Alert |
02/22/2022 | Buy Now | 130% | Raymond James | — | $28 → $23 | Downgrade | Strong Buy → Outperform | Get Alert |
The latest price target for Profound Medical (NASDAQ:PROF) was reported by Stifel on July 16, 2024. The analyst firm set a price target for $12.00 expecting PROF to rise to within 12 months (a possible 20.00% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Profound Medical (NASDAQ:PROF) was provided by Stifel, and Profound Medical upgraded their buy rating.
The last upgrade for Profound Medical Corp happened on July 16, 2024 when Stifel raised their price target to $12. Stifel previously had a hold for Profound Medical Corp.
The last downgrade for Profound Medical Corp happened on August 4, 2023 when Raymond James changed their price target from N/A to N/A for Profound Medical Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a upgraded with a price target of $9.00 to $12.00. The current price Profound Medical (PROF) is trading at is $10.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.